Infantile Hemangioma

Clinical Snapshot

An infantile hemangioma (IH) is a benign vascular tumour of infancy arising from abnormal proliferation of endothelial cells that stain positive for GLUT1 (erythrocyte-type glucose transporter protein) — a distinguishing immunohistochemical marker not present in other benign vascular tumours and, critically, not present in vascular malformations, the other major category of "birthmark" that IH is frequently confused with.^[1] IH is the single most common benign tumour of infancy, affecting an estimated 4-10% of infants overall, with the more precise and commonly cited figure — the working estimate this chapter uses — closer to 4-5%.^[2]^[1]

Most IH are small, innocuous, and need no treatment beyond reassurance and watchful waiting: the defining natural history of an IH is a period of rapid growth followed by spontaneous regression, and the large majority of lesions never threaten function, cause meaningful pain, or leave a lasting cosmetic trace. But up to 15% of IH develop a genuine complication — ulceration, pain, functional impairment, or a real risk of permanent disfigurement — and this minority is what this chapter is built around.^[2] For those infants, oral propranolol is now the guideline-endorsed, first-line treatment, having displaced systemic corticosteroids as the standard of care over the past decade and a half on the strength of a substantially better efficacy and safety profile.^[1]^[3] Timing matters here more than in almost any other chapter in this library: because the most rapid IH growth happens in the first few months of life, the practical window to intervene before growth — and any resulting damage — is complete is genuinely narrow, and recognizing a high-risk IH early, ideally within the first month or two of life, is one of the single most consequential things a pharmacist or primary care clinician can do for these patients.^[1]^[2]

Recognize the Condition

The growth cycle — why timing is the whole story

Unlike most conditions in this library, IH follows a genuinely predictable, well-characterized three-phase natural history, and where a given lesion sits on that timeline is often more clinically important than its size or appearance on any single visit.

The three phases

Proliferative phase

The most rapid growth occurs between 1 and 3 months of age, and growth is largely complete by 5 months in most lesions^[1] — though larger, deeper, or mixed (combined) IH can continue growing more slowly out to 12 months of age.^[2] This is the critical treatment-decision window: intervention started while a lesion is still actively proliferating is far more effective at limiting ultimate size and preventing complications than intervention started after growth has already run its course.

Plateau phase

A period of relative stability, typically running from roughly 12 to 18 months of age, during which the lesion neither grows nor regresses meaningfully.^[2]

Involuting phase

Spontaneous regression that plays out over subsequent years — roughly 1 to 7 years of age, with about 90% of lesions substantially resolved by age 4.^[2] This is an important reassurance and expectation-setting point for the many uncomplicated IH that never need active treatment. Involution is not always complete, however: roughly half of untreated IH leave some residual fibrofatty tissue, atrophy, scarring, or redundant skin behind.^[2]

What a classic IH looks like at each stage

A raised, lobulated, bright red superficial infantile hemangioma on an infant

A classic superficial ("strawberry") infantile hemangioma in the proliferative phase — raised, lobulated, and bright red. (Zeimusu, public domain, Wikimedia Commons)

An infantile hemangioma in the involuting phase, still a raised pink-red vascular lesion but with early softening and colour change

An infantile hemangioma in the involuting phase — still a raised vascular lesion, but with the softening and colour change that mark the transition out of active proliferation. (Gstk, CC BY-SA 4.0, Wikimedia Commons)

A flat, later-stage infantile hemangioma illustrating the flattening and colour fading of later involution

A flat infantile hemangioma later in involution, illustrating the gradual flattening and colour fading that most lesions undergo over the following years. (Gstk, CC BY-SA 4.0, Wikimedia Commons)

Classification — depth and anatomic pattern

By soft-tissue depth

Superficial

Red, with little or no subcutaneous component — the classic "strawberry" hemangioma.^[1]

Deep

Blue and located below the visible skin surface — historically called a "cavernous" hemangioma; often presents a little later than a superficial lesion, since it lacks the same early red colour change at the surface.^[1]

Mixed (combined)

Both a superficial and a deep component are present.^[1]

IH are also classified by anatomic pattern, and this distinction genuinely matters for risk: a localized/focal IH is a well-defined lesion that appears to arise from a single central point, while a segmental IH covers a broader anatomic territory — often plaque-like, frequently more than 5 cm in diameter, and arising across one or more developmental units. Segmental IH, and especially large segmental facial IH, carry meaningfully higher risk of ulceration, disfigurement, and an associated structural anomaly (PHACE or LUMBAR syndrome — see Assessment/Diagnosis and Special Populations) than a comparably sized focal lesion.^[1] Indeterminate (partial segmental) IH fall between these two patterns, and multifocal IH — 5 or more discrete lesions at separate sites — raise a specific concern for hepatic and other visceral hemangiomas (see Assessment/Diagnosis).^[1]

Risk Factors

Who develops IH

Female sex — IH occur more often in girls than boys.^[1]
Multiple gestation (twins).^[1]
Prematurity and low birth weight — risk rises sharply as birth weight falls; as many as 30% of infants born weighing under 1 kg develop an IH.^[1]
White race/ethnicity, relative to other groups.^[1]
A family history of IH is reported anecdotally, though the genetics remain incompletely defined. The leading pathogenetic hypothesis involves circulating endothelial progenitor cells migrating to sites where local conditions (hypoxia, developmental field disturbances) favour their proliferation, but the underlying cause is not yet fully established.^[1]

Why some IH become high risk

The great majority of IH are none of the following — but up to about 1 in 6 or 1 in 7 IH develops a genuine complication, and recognizing which lesions are more likely to fall into that group is the entire purpose of the risk-stratification framework covered in Assessment/Diagnosis.^[2] The clinical findings that push an IH into the high-risk category are not about a lesion being "bad" in a vague sense — each maps to a specific, named risk: a life-threatening complication (airway or hepatic involvement), functional impairment (vision, feeding), ulceration, an associated structural anomaly (PHACE, LUMBAR), or a genuine risk of permanent disfigurement.^[1]

Red Flags & Refer

Any of the following changes the plan from "observe and reassure" to prompt hemangioma-specialist referral and evaluation:

Any IH causing, or at meaningful risk of causing, airway compromise — a segmental IH in a "beard distribution" (chin, jaw line, lower lip, anterior neck) is the strongest single predictor of an airway IH, and stridor or a biphasic/barky cough in an infant with a cutaneous beard-distribution IH should not be dismissed as croup or reactive airway disease. About half of infants with an airway IH also have a cutaneous IH as the visible clue.^[1]
Periocular IH, especially over 1 cm — untreated, these carry a real risk of astigmatism, anisometropia, proptosis, and amblyopia, and warrant urgent ophthalmology involvement alongside hemangioma-specialist referral, not routine follow-up.^[1]
Ulceration, particularly of a segmental IH involving the lip, columella, ear (superior helix), gluteal cleft/perineum, or another intertriginous area (neck folds, axillae, groin) — these sites carry a substantially higher ulceration risk than IH elsewhere, and ulceration itself is painful, prone to infection and bleeding, and a guideline-recognized indication for propranolol in its own right.^[1]^[3]
5 or more cutaneous IH — screen for hepatic IH (see Assessment/Diagnosis); rare but serious hepatic and other visceral involvement can progress to high-output cardiac failure and consumptive hypothyroidism.^[1]
A large (generally over 5 cm) segmental facial or scalp IH — evaluate for PHACE syndrome before starting propranolol, not after (see Special Populations); a large segmental IH of the lumbosacral/perineal area raises the analogous concern for LUMBAR syndrome.^[1]^[4]
Any IH with feeding impairment (lip or oral cavity involvement) or a clear trajectory toward permanent disfigurement (nasal tip, lip, or facial IH 2 cm or larger — or over 1 cm if the infant is 3 months of age or younger — scalp IH over 2 cm, or a female infant with a breast IH) — refer for hemangioma-specialist evaluation, ideally by 1 month of age, without waiting to see how the lesion "does."^[1]

Assessment & Diagnosis

Diagnosis is clinical

IH is diagnosed clinically in the overwhelming majority of cases, based on the characteristic appearance and — just as importantly — the characteristic growth trajectory described above. A lesion that is absent or barely visible at birth and then grows rapidly over the first weeks to months of life is behaving like an IH in a way that a vascular malformation (present at birth, growing proportionately with the child, never truly regressing) and a congenital hemangioma (fully formed at birth) do not.^[1]

The key differential: IH vs. congenital hemangioma vs. vascular malformation

A congenital hemangioma is fully developed at birth — unlike a true IH, which is often minimal or absent at birth and grows postnatally — and is GLUT1-negative; it does not respond to propranolol or corticosteroids and follows one of three distinct patterns: rapidly involuting (RICH, which typically regresses on its own within the first 1-2 years and rarely needs treatment), non-involuting (NICH, which persists unchanged and may need surgical excision), or partially involuting (PICH).^[2] A vascular malformation (for example a port-wine stain/capillary malformation) is also present at birth, grows proportionately with the child rather than in IH's distinctive rapid-then-regressing pattern, and never truly involutes on its own.^[1]

When to image

Most IH do not need imaging at all — reserve it for genuine diagnostic uncertainty rather than ordering it reflexively.

Do not image unless the diagnosis is uncertain, there are 5 or more cutaneous IH, or an associated structural anomaly is suspected.^[1]
Ultrasound (with Doppler) is the initial imaging modality of choice when the diagnosis is uncertain — no sedation, no ionizing radiation; most IH appear as a well-defined, high-flow mass without arteriovenous shunting (an important exception: hepatic IH can show arteriovenous shunting).^[1] Abdominal ultrasonography (roughly 95% sensitivity for hepatic IH) is specifically recommended to screen for hepatic involvement in any infant with 5 or more cutaneous IH.^[1]
MRI (± MRA of the head and neck, and echocardiography including the aortic arch) is indicated when there is concern for an associated structural anomaly — PHACE or LUMBAR syndrome — most often triggered by a large (over 5 cm) segmental facial/scalp IH or a segmental lumbosacral/perineal/gluteal IH. This work-up should be completed before, or very shortly after, starting propranolol in this specific group, not deferred.^[1]^[4]^[3]
CT is not the modality of choice for IH given the ionizing radiation involved, particularly in young infants.^[1]

Risk stratification — the framework that drives every treatment decision

Classify every IH as high-risk if there is evidence of, or potential for, any of the following.^[1]

Category	Representative findings	Why it matters
Life-threatening	"Beard-distribution" segmental IH; 5 or more cutaneous IH	Obstructive airway hemangioma; hepatic IH with high-output cardiac failure and/or consumptive hypothyroidism
Functional impairment	Periocular IH over 1 cm; IH involving the lip or oral cavity	Astigmatism, anisometropia, proptosis, amblyopia; feeding impairment
Ulceration	Segmental IH of any size involving the lips, columella, ear (superior helix), gluteal cleft/perineum, or another intertriginous area (neck folds, axillae, groin)	Increased ulceration risk — painful, prone to infection/bleeding
Associated structural anomaly	Segmental IH of the face/scalp; segmental IH of the lumbosacral/perineal area	PHACE syndrome; LUMBAR syndrome (see below)
Disfigurement	Segmental facial/scalp IH; nasal tip or lip IH of any size, or facial IH 2 cm or larger (over 1 cm if the infant is 3 months or younger); scalp IH over 2 cm; neck/trunk/extremity IH over 2 cm; breast IH in a female infant	Distortion of anatomic landmarks; permanent alopecia/scarring; permanent changes in breast development or nipple contour

^[1]

PHACE and LUMBAR syndrome — a brief orientation

PHACE syndrome (Posterior fossa malformations, segmental facial Hemangioma, Arterial anomalies, Cardiac anomalies/aortic coarctation, and Eye anomalies, ± sternal defects — "PHACES") is diagnosed by consensus criteria: a head/scalp hemangioma over 5 cm in diameter plus 1 major or 2 minor criteria, or a hemangioma of the neck, upper trunk, or proximal upper extremity plus 2 major criteria, drawn from cerebrovascular, cardiovascular, ocular, and ventral/midline-defect categories.^[4] LUMBAR syndrome is its lower-body counterpart — Lower body IH with Urogenital anomalies and/or Ulceration, Myelopathy, Bony deformities, Anorectal malformations and arterial anomalies, and Renal anomalies — associated with a segmental IH of the lumbosacral, gluteal, or perineal area.^[1] See Special Populations for the specific screening work-up.

Treatment Targets

Correctly distinguish the large majority of IH that need only observation and parent education from the minority that need active treatment, using the risk-stratification framework above rather than gestalt.
For high-risk IH, intervene during the proliferative phase — the window in which treatment most effectively limits ultimate size and prevents complications — rather than waiting to "see how it grows."^[1]
Arrest proliferative growth and accelerate involution with first-line pharmacotherapy.^[1]^[3]
Prevent and manage the specific complications that drive most of this chapter's morbidity: ulceration, and functional impairment from a high-risk location (airway, periocular, oral).^[1]
Screen appropriately for PHACE/LUMBAR syndrome and hepatic involvement before committing to systemic therapy in the specific groups at risk.^[4]^[1]
Minimize long-term cosmetic sequelae, recognizing that roughly half of untreated IH leave some residual skin change behind.^[2]
Use propranolol safely — real cardiovascular and metabolic risk exists, especially with the first dose and each dose increase — rather than either avoiding an indicated, guideline-endorsed treatment out of excess caution, or underestimating its monitoring requirements.^[3]
Set families up for a safe course: feeding-timed dosing, hold-dose instructions for illness/poor intake, and a clear plan for the eventual taper/stop and rebound-growth risk.^[3]^[1]

Choose Initial Treatment

Direct treatment rule — deciding whether to treat

Treat when an IH meets one or more high-risk criteria above — a life-threatening complication, functional impairment or its risk, ulceration or its risk, an associated structural anomaly requiring evaluation, or a genuine risk of permanent scarring/disfigurement.^[1] Observe only is appropriate — and is in fact the right choice — for the large majority of IH: small, low-risk-location lesions with no evidence of ulceration or functional threat do not need pharmacotherapy, and watchful waiting with parent education about the expected growth-then-involution course is genuinely the correct plan, not a default born of inaction.^[1]^[2]

Refer promptly — ideally by 1 month of age — for hemangioma-specialist evaluation of any high-risk IH; because the treatment window is tied to the proliferative phase, a delayed referral can mean a delayed, and less effective, treatment start.^[1] CPS guidance frames the same urgency slightly differently: refer as soon as possible, and ideally before 4 months of age, for eye, nose, urethral, anal, or hepatic involvement, a large facial IH, more than 5 cutaneous lesions, or any IH with an inadequate response to, or an adverse effect from, propranolol.^[2] Both describe the same underlying principle — the earlier a high-risk IH reaches a clinician experienced in its management, the better the outcome.

Direct treatment rule — oral propranolol, the first-line agent

Oral propranolol is recommended as first-line therapy for IH requiring systemic treatment, on the strength of a substantially better efficacy and safety profile than the corticosteroid therapy it has displaced: in a network meta-analysis, propranolol achieved a mean 95% clearance rate (95% credible interval 88-99%), versus 58% for intralesional triamcinolone, 43% for oral corticosteroids, and 6% for untreated controls.^[1] In the pivotal randomized, placebo-controlled trial that established the modern dosing regimen, oral propranolol 3 mg/kg/day for 6 months achieved complete or near-complete resolution in 60% of infants, versus 4% on placebo (P<.0001).^[5] In Canada, propranolol is specifically approved (as Hemangiol, a strawberry-vanilla-flavoured oral solution formulated and dosed for this indication) for proliferating IH requiring systemic therapy: a life- or function-threatening IH, an ulcerated IH with pain and/or a lack of response to simple wound-care measures, or an IH with a genuine risk of permanent scarring or disfigurement.^[3]

Before starting. Treatment is initiated in infants aged 5 weeks to 5 months, with the age window corrected for prematurity.^[3] Take a full history and clinical exam — including heart rate and cardiac/pulmonary auscultation — before the first dose; if a cardiac abnormality is suspected, obtain specialist advice before starting rather than proceeding and re-evaluating later.^[3] Routine baseline ECG is not required by current FDA or Health Canada labelling; a more selective approach — reserving ECG for an infant with a baseline heart rate below normal for age, a family history of congenital heart disease or arrhythmia (or a maternal history of connective tissue disease), or a personal history/exam finding of arrhythmia — has been proposed as a reasonable standard to expect from a hemangioma specialist's work-up.^[1] For a large segmental facial IH, complete PHACE screening (MRI/MRA of the head and neck including the aortic arch, and echocardiography) before, or very shortly after, starting propranolol — see Special Populations.^[3]^[4]

Dosing and titration. The therapeutic target is 2-3 mg/kg/day (expressed as propranolol base), and Canadian product labelling specifies a structured 3-week titration to get there, given twice daily at least 9 hours apart, during or immediately after a feed:

Week 1: 0.5 mg/kg twice daily (1 mg/kg/day total).
Week 2: 1 mg/kg twice daily (2 mg/kg/day total).
Week 3 onward (maintenance): 1.5 mg/kg twice daily (3 mg/kg/day total).^[3]

The first dose and every dose increase must be given in a controlled clinical setting with the ability to manage an urgent adverse event, with heart rate and blood pressure checked at least hourly for at least 2 hours afterward, watching specifically for bradycardia, hypotension, bronchial hyperreactivity, and hypoglycemia.^[3] Bradycardia is defined as a heart-rate decline of more than 30 bpm from baseline; discontinue and seek immediate specialist advice for symptomatic bradycardia, severe bradycardia (under 80 bpm), severe hypotension (systolic under 50 mmHg), or Grade II/III heart block.^[3] The site of initiation (inpatient versus outpatient) has genuinely evolved as more real-world safety data has accumulated: brief inpatient initiation is still generally favoured for infants younger than 8 weeks, those with a cardiovascular or respiratory comorbidity, or those with poor social support, while outpatient initiation with in-office monitoring is an accepted approach for an otherwise healthy infant older than 5 weeks' corrected gestational age.^[1] CPS guidance adds a practical nuance for slower titration: escalate more cautiously — for example weekly increases of 0.5-1 mg/kg/day rather than the full weekly step — in neonates, infants under 2 months corrected age, or suspected PHACE syndrome.^[2] After the titration phase, re-examine the child and re-adjust the dose for weight at least monthly.^[3]

The feeding connection — why this matters specifically for hypoglycemia. Propranolol blunts the catecholamine-driven counter-regulatory response to hypoglycemia and can mask its usual adrenergic warning signs (tachycardia, shakiness, anxiety, hunger); in an infant, hypoglycemia can instead present atypically — irritability, lethargy, nightmares or crying out during sleep, unusual sleepiness, or, in a genuine emergency, a hypoglycemic seizure or coma.^[3] Give every dose during or immediately after a feed, and schedule the second daily dose in the late afternoon specifically to reduce the risk of nocturnal hypoglycemia while the infant and caregivers are both likely to be asleep.^[3] Hold the dose for vomiting, feeding difficulty, or suspected hypoglycemia, and counsel caregivers to keep the infant on a regular feeding schedule and to have the same person handle both the medication and the feed, to avoid an accidental missed feed or double dose.^[3] If clinical signs of hypoglycemia appear, interrupt treatment, give a sugary liquid, and seek immediate medical attention.^[3]

Duration and stopping. Treatment is typically continued for at least 6 months, and is often maintained until 12 months of age (occasionally longer), reflecting that growth in larger, deeper, or mixed IH can continue beyond the classic 5-month proliferative window.^[1] No down-titration is required at the end of a course.^[3] Discontinue if there is no improvement at all within the first 2 months — that is a genuine treatment failure, not a reason to extend empirically.^[3] Rebound growth after stopping (or during a taper) is a real and reasonably common possibility — occurring in roughly 10% to 25% of infants, even after a full 6 months of therapy — and is most likely when treatment is stopped before 12 months of age (especially before 9 months) and least likely when stopped between 12 and 15 months of age; mixed/deep morphology and female sex are additional risk factors for rebound.^[1] These observations are why many hemangioma specialists now favour continuing therapy to at least 1 year of age rather than stopping strictly at the 6-month mark.^[1]

Adverse effects to counsel on. The most frequently reported effects (each in over 10% of treated infants in the pivotal trials) were sleep disturbance, aggravated respiratory tract infection (bronchitis/bronchiolitis), diarrhea, and vomiting; treatment was discontinued for an adverse event in about 2.5% of treated infants.^[3] The adverse effects that matter most clinically are the ones that mirror the initial-dose monitoring above — clinically symptomatic bradycardia and hypotension, bronchospasm/bronchial hyperreactivity (hold the dose for a lower respiratory tract infection with dyspnea or wheezing), and hypoglycemia — plus hyperkalemia, which has been reported specifically in infants with a large ulcerated IH and warrants electrolyte monitoring in that group.^[3]^[1]

Direct treatment rule — topical timolol maleate

Topical timolol maleate 0.5% (the same gel-forming ophthalmic solution formulated for glaucoma, used here off-label on the skin) is a reasonable therapy for a thin, superficial IH that does not meet high-risk criteria — genuinely lower systemic exposure than oral propranolol, though it is the same drug class and not free of systemic beta-blocker effect, particularly if applied to ulcerated skin or a larger surface area.^[1] A randomized, placebo-controlled trial in 41 infants with superficial IH (median age 9 weeks) found a significant improvement in blinded photographic colour scores by 24 weeks with timolol gel dosed twice daily, compared with placebo.^[6] In the same network meta-analysis cited above, topical timolol's mean clearance rate was 62% (95% credible interval 39-83%) — meaningfully better than placebo/observation, but well short of oral propranolol's 95%, which is exactly why it is reserved for lower-risk lesions rather than substituted for propranolol once a high-risk feature is present.^[1] CPS guidance describes 1-2 drops applied to the lesion twice daily; oral propranolol remains preferred for any IH that is large, ulcerated, or otherwise high-risk.^[2]

Direct treatment rule — when propranolol is not the answer

Contraindicated, poorly tolerated, or an inadequate response to oral propranolol oral prednisolone or prednisone is a reasonable second-line systemic option — this was the standard of care for decades before propranolol's superior efficacy and safety profile displaced it, and it remains genuinely useful in this specific circumstance.^[1] Its mean clearance rate (43%) is meaningfully lower than propranolol's, and it carries its own real harms — Cushingoid features, increased infection risk, growth retardation, hypertension, and mood changes — that need to be weighed and monitored over the treatment course.^[1] Combining an oral corticosteroid with propranolol also increases hypoglycemia risk, through loss of the counter-regulatory cortisol response — a genuine interaction to flag if both are ever used together.^[3]

Focal, bulky IH during proliferation, or IH in certain critical anatomic locations (e.g., the lip) intralesional triamcinolone and/or betamethasone injection is a reasonable option, typically repeated every 4-6 weeks as needed; mean clearance is comparable to oral corticosteroids (58%), with a different harm profile — local fat and dermal atrophy, pigmentary change, and, rarely, central retinal artery embolization (most often after upper-eyelid injection at high pressure or volume) — and adrenal suppression has been reported at higher cumulative doses (over roughly 4 mg/kg).^[1]

Residual skin change after involution, or select cases earlier in the course surgery and/or laser treatment are most useful for addressing the fibrofatty tissue, redundant skin, scarring, or telangiectasia that can remain after involution, and are occasionally considered earlier for a specific subset of IH (for example a pedunculated lesion, or a well-localized lesion for which early excision is reasonable).^[1]

Non-Pharmacologic Treatment

Watchful waiting with parent education is genuinely the correct treatment for the majority of IH — small, low-risk-location, uncomplicated lesions do not need pharmacotherapy, and setting expectations for the proliferative-plateau-involuting course (including that roughly half of untreated lesions leave some residual skin change) is itself a meaningful intervention.^[1]^[2]
Wound care for an ulcerated IH — gentle cleansing, a non-adherent barrier dressing, and topical or, for pain, systemic analgesia — is first-line for a mild ulceration; escalate to systemic propranolol specifically when simple wound care fails or the ulcer is painful, per the Hemangiol indication itself.^[3]
Compression or cosmetic camouflage can be a reasonable adjunct or bridge for families managing the visible impact of a lesion during the proliferative phase while a treatment decision is being made, though this is supportive rather than disease-modifying.
Surgery and/or laser treatment (pulsed-dye laser for residual telangiectasia/erythema; surgical excision for fibrofatty residue or redundant skin) are most useful once involution is complete, and are occasionally reasonable earlier in select IH.^[1]
Psychosocial support for parents matters in its own right — the visible, sometimes rapidly changing nature of a facial IH during proliferation is genuinely distressing for many families, independent of the lesion's actual medical risk, and acknowledging that distress is part of good care.

Pharmacologic Treatment Options

Drug / intervention	Role	Dose / use	Important adverse effects	Teaching points
Propranolol Preferred	First-line for IH requiring systemic therapy (life/function-threatening, ulcerated with pain or no response to wound care, or risk of permanent disfigurement)	Titrate over 3 weeks to 3 mg/kg/day (1.5 mg/kg twice daily); see Choose Initial Treatment/Drug Tables for the full week-by-week schedule	Bradycardia, hypotension, hypoglycemia (can be masked/atypical), bronchospasm, sleep disturbance	Give with/after feeds; monitor heart rate/blood pressure hourly for 2 hours after the first dose and each increase; hold the dose for vomiting or poor intake.
Timolol maleate 0.5% gel-forming solution Alternative	Small, thin, superficial, low-risk IH only	1-2 drops applied to the lesion twice daily	Systemic beta-blocker effects are possible, especially on ulcerated skin or a large surface area, though less than with oral propranolol	Not a substitute for propranolol once a high-risk feature (ulceration, high-risk location, large/deep lesion) is present.
Prednisone Special situation	Propranolol contraindicated, poorly tolerated, or an inadequate response	Individualized; historic regimens generally 2-3 mg/kg/day, tapered over weeks	Cushingoid features, growth retardation, hypertension, increased infection risk, mood changes	Was the prior standard of care; now second-line given propranolol's superior efficacy and safety profile.
Intralesional triamcinolone/betamethasone Special situation	Focal, bulky IH during proliferation, or a critical location (e.g., the lip)	Individualized; injections typically repeated every 4-6 weeks	Local fat/dermal atrophy, pigmentary change; rare central retinal artery embolization (upper eyelid); adrenal suppression at higher cumulative doses	Reserve for relatively small, well-localized lesions; not appropriate for a large or diffuse IH.

Special Populations

PHACE syndrome

PHACE syndrome should be screened for before starting propranolol in any infant with a large (generally over 5 cm) segmental facial or scalp IH — work-up includes MRI and MRA of the head and neck (including the aortic arch and brachiocephalic vessels) and echocardiography, with specialist advice sought before treatment.^[3]^[4] The diagnosis is made against consensus criteria drawn from cerebrovascular (posterior fossa anomalies, arterial anomalies such as dysplasia or an aberrant origin), cardiovascular (aortic arch anomalies including coarctation), ocular, and ventral/midline-defect (sternal defects, supraumbilical raphe) categories — a head/scalp hemangioma over 5 cm plus 1 major or 2 minor criteria, or a hemangioma of the neck/upper trunk/proximal upper extremity plus 2 major criteria.^[4] This screening matters clinically, not just diagnostically: propranolol lowers blood pressure and can theoretically increase stroke risk in a PHACE-syndrome infant with a significant cerebrovascular arteriopathy by reducing flow through an already narrowed or occluded vessel, so confirming the vascular anatomy first — and titrating more slowly and cautiously if therapy proceeds — is a genuine safety step, not a formality.^[3]^[2]

LUMBAR syndrome

A segmental IH of the lumbosacral, gluteal, or perineal area raises the analogous concern for LUMBAR syndrome; screening (spinal ultrasound for a corrected age under 6 months, or MRI, plus renal/pelvic imaging) should be considered, particularly if markers of spinal dysraphism (a sacral dimple, skin appendage, tuft of hair, or lipoma) are also present.^[1]

Hepatic and multifocal IH

Hepatic hemangiomas occur in 3 patterns — focal, multifocal, and diffuse. Most multifocal hepatic IH are asymptomatic and need no treatment, but a minority are associated with high-flow macrovascular shunting that can, rarely, cause high-output cardiac failure; the rare diffuse pattern carries the greatest risk of morbidity, typically presenting before 4 months of age with severe hepatomegaly and a risk of abdominal compartment syndrome and a consumptive hypothyroidism from type 3 iodothyronine deiodinase activity within the IH tissue.^[1] Screening abdominal ultrasonography is recommended for any infant with 5 or more cutaneous IH, since the risk of liver involvement rises meaningfully in this group.^[1]

Prematurity and low birth weight

Propranolol is contraindicated in a premature infant who has not yet reached 5 weeks of corrected age, and in any infant weighing under 2.5 kg; the age window for starting therapy is corrected for prematurity throughout.^[3] A more cautious, slower dose titration is reasonable in a neonate or an infant under 2 months corrected age.^[2]

Pregnancy and breastfeeding

Hemangiol is not intended to be prescribed to pregnant or nursing women — it is an infant-specific formulation, and propranolol treatment has been associated with embryotoxicity in animal studies.^[3] Propranolol does pass into breast milk; if an infant being treated with Hemangiol is also breastfed, confirm the mother is not taking a medication that is itself contraindicated with propranolol, since that combination is a specific contraindication to continuing Hemangiol therapy in the infant.^[3]

Renal impairment

Hemangiol has not been studied in infants with impaired renal function and is not recommended in this population in the absence of data; propranolol and its metabolites are renally excreted, and adult data show 3- to 6-fold higher peak concentrations and decreased clearance in dialysis and chronic renal failure, respectively.^[3]

Hepatic impairment

Hemangiol has not been studied in infants with impaired hepatic function and is not recommended in this population in the absence of data; propranolol is hepatically metabolized, and adult cirrhosis data show roughly 3-fold higher steady-state concentrations and a longer terminal half-life (about 11 hours versus 4 hours) compared with healthy subjects.^[3]

Peri-operative considerations

Beta-blockers can interact with anesthetic agents, blunting reflex tachycardia and increasing hypotension risk; hold propranolol at least 48 hours before any procedure requiring anesthesia, and alert the anesthetist that the infant is being treated with a beta-blocker.^[3]

Monitoring & Follow-Up

Monthly clinical review and weight-based dose re-adjustment throughout the propranolol course.^[3]
Set realistic expectations for response timing: an initial response is typically seen within 3-4 weeks, though a visible colour change is often noted within the first 48 hours of starting treatment.^[2]
Confirm caregivers can recognize the atypical, masked infant presentation of hypoglycemia (irritability, lethargy, unusual sleepiness, nightmares or crying out during sleep) rather than expecting the classic adult adrenergic picture that propranolol itself blunts.^[3]
Confirm the feeding-timed dosing routine (with/after feeds, second dose in late afternoon, hold for vomiting/poor intake, same caregiver handles medication and feed) is genuinely being followed at each visit, not just explained once at the start.^[3]
Track objective growth or regression of the lesion — consistent, comparably lit photographs at each visit are a practical way to confirm response and to catch a genuine non-responder early rather than late.
At the end of a course, counsel explicitly on rebound-growth risk (roughly 10-25%, highest if stopped before 12 months of age) and arrange a specific follow-up visit rather than leaving re-evaluation to chance.^[1]
For a patient on oral or intralesional corticosteroid therapy, monitor growth parameters, blood pressure, and for signs of infection or mood change over the treatment course.^[1]
Educate every caregiver, regardless of the treatment chosen, about the expected natural history of IH and its potential for causing complications or disfigurement — this is a Key Action Statement in its own right, not an afterthought once a prescription is written.^[1]

Treatment Failure / Next Step

No improvement at all within the first 2 months of oral propranolol at an adequate dose: this is a genuine treatment failure per Canadian labelling — reassess the diagnosis, confirm adherence and dosing, and check whether a comorbidity (or a dose reduction made for another reason) has kept the dose below target, rather than simply continuing unchanged.^[3]
Propranolol-associated bronchospasm with a lower respiratory tract infection: interrupt therapy; only consider re-starting once the infant has fully recovered, confirmed by a full clinical exam including auscultation; permanently discontinue if bronchospasm recurs, or if isolated bronchospasm or asthma is diagnosed.^[3]
Rebound growth after stopping, or during a taper: re-initiate propranolol under the same monitoring conditions as the original start, rather than assuming the treatment window has passed.^[3]^[1]
An ulcerated IH not responding to propranolol plus simple wound care: reassess for infection, escalate wound care, and consider pain control; an ulcer that continues to fail therapy warrants hemangioma-specialist reassessment rather than an indefinite trial of the same regimen.
A genuine propranolol contraindication (true asthma/reactive bronchospasm history, symptomatic bradycardia, heart block) or a poor/inadequate response despite adequate dosing and duration: move to oral or intralesional corticosteroid therapy as above, rather than persisting with an ineffective or unsafe propranolol course.^[1]
Significant residual skin change once involution is complete, or substantially complete: refer for consideration of surgery and/or laser treatment rather than continuing to "wait and see" indefinitely.^[1]

Common Errors to Avoid

Treating every IH with propranolol regardless of risk — most IH are low-risk and genuinely need only observation and parent education; pharmacotherapy is for the high-risk minority.^[1]^[2]
Waiting to see how a high-risk IH "does" before referring, rather than referring promptly (ideally by 1 month of age) — the treatment window is tied to the proliferative phase, and a delayed start is a genuinely less effective start.^[1]
Starting or increasing propranolol without the required in-clinic monitoring window (heart rate/blood pressure at least hourly for at least 2 hours) after the first dose and every dose increase.^[3]
Missing the atypical, masked presentation of infant hypoglycemia on propranolol because it does not look like the adult adrenergic picture (tachycardia, shakiness) that propranolol itself blunts.^[3]
Dosing propranolol without regard to feeds, or scheduling the second daily dose late enough at night that a hypoglycemic episode would go unnoticed during sleep.^[3]
Assuming a beard-distribution or anterior-neck IH with stridor is croup or reactive airway disease rather than considering an airway IH.^[1]
Starting propranolol in a large segmental facial IH without completing PHACE screening first — a significant cerebrovascular anomaly in PHACE syndrome can make the blood-pressure-lowering effect of propranolol genuinely dangerous.^[3]^[4]
Reaching for topical timolol as a substitute for oral propranolol once a high-risk feature (ulceration, a high-risk location, a large/deep lesion) is present — it is a reasonable option only for low-risk, thin, superficial IH.^[1]
Stopping propranolol abruptly at exactly 6 months in a still-actively-growing lesion, and failing to counsel on rebound-growth risk, particularly if therapy stops before 12 months of age.^[1]
Continuing an ineffective propranolol course past 2 months with no improvement at all, rather than recognizing this as a defined treatment failure.^[3]

Clinical Decision Algorithm

Algorithm A — Recognition and risk stratification

Suspected infantile hemangioma — a vascular lesion absent or minimal at birth, growing over the first weeks to months of life

Confirm the diagnosis clinically (appearance plus growth trajectory); classify by depth (superficial/deep/mixed) and pattern (focal/segmental/multifocal)^[1]

No high-risk feature present (small, low-risk location, no ulceration, no functional threat)

Observe — watchful waiting with parent education on the expected proliferative-plateau-involuting course

One or more high-risk features present: life-threatening complication, functional impairment/risk, ulceration/risk, associated structural anomaly, or risk of permanent disfigurement

Refer promptly to a hemangioma specialist — ideally by 1 month of age^[1]

Proceed to Algorithm B (pharmacotherapy) after appropriate screening

Algorithm B — Propranolol initiation and titration

High-risk IH, candidate for oral propranolol

Pre-treatment screening: history and exam (heart rate, cardiac/pulmonary auscultation); selective ECG only if indicated; for a large segmental facial IH, complete PHACE work-up (MRI/MRA head and neck, echocardiography) first^[3]^[4]^[1]

Age under 5 weeks corrected, weight under 2.5 kg, or a genuine contraindication (2nd/3rd-degree heart block, sinus node disease, uncontrolled heart failure, asthma/bronchospasm history, cardiogenic shock)

Do not start propranolol — consider oral or intralesional corticosteroid instead (see Choose Initial Treatment)^[3]

Eligible

Week 1: 0.5 mg/kg twice daily (1 mg/kg/day) with/after feeds^[3]

Monitor heart rate/blood pressure hourly for 2 hours after the first dose — watch for bradycardia, hypotension, bronchial hyperreactivity, hypoglycemia^[3]

Week 2: 1 mg/kg twice daily (2 mg/kg/day), same monitoring after the increase^[3]

Week 3 onward: 1.5 mg/kg twice daily (3 mg/kg/day) — maintenance target^[3]

Continue for at least 6 months, often to 12 months of age; monthly weight-based dose review^[1]

At the planned stop, or with rebound growth: counsel on roughly 10-25% rebound risk, highest if stopped before 12 months of age; re-initiate under the same monitoring conditions if rebound occurs^[1]

Algorithm C — Alternative pathways when propranolol is not the answer

Propranolol contraindicated, not tolerated, or an inadequate response after an adequate trial

Small, thin, superficial, low-risk IH only

Topical timolol maleate 0.5%, 1-2 drops to the lesion twice daily^[2]^[1]

Focal, bulky IH during proliferation, or a critical location (e.g., the lip)

Intralesional triamcinolone and/or betamethasone, repeated every 4-6 weeks as needed^[1]

Any IH still requiring systemic therapy

Oral prednisolone or prednisone^[1]

After involution, or for a specific residual concern: surgery and/or laser for residual skin change^[1]

Drug Tables

Oral Propranolol — First-Line Systemic Therapy (Hemangiol, Health Canada)

The complete 3-week weight-based titration schedule; give twice daily, at least 9 hours apart, during or immediately after a feed.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Propranolol	Week 1: 0.5 mg/kg PO twice daily (1 mg/kg/day total). Week 2: 1 mg/kg PO twice daily (2 mg/kg/day total). Week 3 onward (maintenance): 1.5 mg/kg PO twice daily (3 mg/kg/day total). Continue for at least 6 months, often to 12 months of age.	Bradycardia, hypotension, hypoglycemia (may be masked/atypical), bronchospasm/bronchial hyperreactivity, sleep disturbance, GI upset, hyperkalemia (large ulcerated IH)	Anesthetic agents (hold at least 48 hours pre-operatively); other antihypertensives/negative chronotropes; oral corticosteroids (additive hypoglycemia risk via loss of cortisol counter-regulation)	First dose and each dose increase require in-clinic heart rate/blood pressure monitoring at least hourly for at least 2 hours. Contraindicated: age under 5 weeks corrected, weight under 2.5 kg, asthma/bronchospasm history, 2nd/3rd-degree heart block, sinus node disease, age-based bradycardia/hypotension thresholds, cardiogenic shock, uncontrolled heart failure, Prinzmetal angina, severe peripheral arterial circulatory disturbance, hypoglycemia-prone states, pheochromocytoma.^[3]

Topical and Second-Line Systemic/Intralesional Therapy

Reserved for low-risk lesions (topical timolol) or for when propranolol is contraindicated, not tolerated, or inadequately effective.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Timolol maleate 0.5% gel-forming solution	1-2 drops applied directly to the lesion twice daily	Systemic beta-blocker effects are possible, especially with application to ulcerated skin or a large surface area; local irritation	As for a systemic beta-blocker, though systemic exposure is meaningfully lower than with oral propranolol	For small, thin, superficial, low-risk IH only — not a substitute for propranolol once a high-risk feature is present.^[2]^[1]
Prednisone	Individualized; historic regimens generally 2-3 mg/kg/day, tapered over weeks	Cushingoid features, growth retardation, hypertension, increased infection risk, mood changes, hyperglycemia	Additive hypoglycemia risk if combined with propranolol, via loss of the cortisol counter-regulatory response	Second-line: propranolol contraindication, intolerance, or inadequate response.^[1]
Prednisolone	Individualized; comparable dosing to prednisone	Same as prednisone	Same as prednisone	An alternative oral corticosteroid to prednisone for the same indication.^[1]
Triamcinolone acetonide (intralesional)	Individualized; injections typically repeated every 4-6 weeks	Local fat/dermal atrophy, pigmentary change; rare central retinal artery embolization (upper eyelid injection); adrenal suppression at higher cumulative doses (over roughly 4 mg/kg)	None significant at standard local doses	Reserve for a focal, bulky, well-localized IH, or a critical location such as the lip.^[1]
Betamethasone (intralesional)	Individualized, often combined with triamcinolone	Same as triamcinolone	None significant at standard local doses	An alternative or adjunct to triamcinolone for intralesional therapy.^[1]

References

Clinical Practice Guideline for the Management of Infantile Hemangiomas — Pediatrics, American Academy of Pediatrics Subcommittee on the Management of Infantile Hemangiomas (Krowchuk DP, Frieden IJ, Mancini AJ, Darrow DH, Blei F, Greene AK, et al.). Pediatrics 2019;143(1):e20183475
Vascular Anomalies in Childhood: When to Treat and When to Refer — Paediatrics & Child Health, Canadian Paediatric Society, Community Paediatrics Committee (Zwicker K, Powell J, Cummings C). Paediatr Child Health 2022;27(5):310-314
HEMANGIOL (propranolol oral solution) Product Monograph Including Patient Medication Information — Pierre-Fabre Dermo-Cosmétique / Health Canada Drug Product Database. Health Canada Product Monograph, Date of Revision February 2, 2018
PHACE Syndrome: Consensus-Derived Diagnosis and Care Recommendations — The Journal of Pediatrics (Garzon MC, Epstein LG, Heyer GL, Frommelt PC, Orbach DB, Baylis AL, et al.). J Pediatr 2016;178:24-33.e2
A Randomized, Controlled Trial of Oral Propranolol in Infantile Hemangioma — New England Journal of Medicine (Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, et al.). N Engl J Med 2015;372(8):735-746
RCT of Timolol Maleate Gel for Superficial Infantile Hemangiomas in 5- to 24-Week-Olds — Pediatrics (Chan H, McKay C, Adams S, Wargon O). Pediatrics 2013;131(6):e1739-e1747

Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.